Communiqués Kamada Ltd.

Actions

KMDA

IL0010941198

Produits pharmaceutiques

Temps Différé TEL AVIV STOCK EXCHANGE 14:42:15 24/08/2026			Varia. 5j.	Varia. 1 janv.
2 441,00 ^ILa	+1,29 %		+6,52 %	+7,79 %

17/08	Kamada réduit son dividende trimestriel à 0,17 $ par action ; versement prévu le 17 septembre pour les actionnaires inscrits au 27 août	MT
17/08	Kamada Ltd. annonce le versement d'un dividende en numéraire le 17 septembre 2026	CI

Communiqués

18/08	Kamada Declares Cash Dividend of $0.17 per Share, the Company Reported Record-High Revenue and Profitability for First Six Months of 2026	AQ
17/08	Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026	AQ
12/08	Kamada: Q2 Earnings Snapshot	AQ
12/08	Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance	AQ
12/08	Kamada Announces Planned Transition of Chief Financial Officer	AQ
05/08	Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026	AQ
20/07	Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies	AQ
13/07	Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting	AQ
01/06	Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory	AQ
13/05	Kamada: Q1 Earnings Snapshot	AQ
13/05	Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year	AQ
06/05	Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026	AQ
31/03	Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders	AQ
26/03	Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas	AQ
11/03	Kamada : Annual Report for Fiscal Year Ending December 31, 2025 (Form 20-F)	PU
11/03	Kamada: Q4 Earnings Snapshot	AQ
11/03	Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth	AQ
11/03	Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy	AQ
04/03	Will release financial results for the Fourth quarter 2025, on March 11, 2026, and will host conference call 8:30am ET	PU
04/03	Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026	AQ
13/01	Kamada Targets 13% Revenue Growth And 23% Adjusted EBITDA Growth In 2026 Driven By Its Diverse Commercial Portfolio	EQ
07/01	Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance	AQ
18/12	Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender	AQ
08/12	Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026	AQ
18/11	Kamada Reports Strongest Quarter For The Year In Q3, With Over 30% Profitability Increase Year-Over-Year	EQ